Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 11/20 | 0.48 |
| ▸ | UMPS | P11172 | 3/20 | 0.42 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.40 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.39 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.39 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.39 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.39 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.39 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7146490 | 0.86 | SLC28A1 (0.51) | P2RY2SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL3212359 | 0.83 | P2RY2 (0.48) | P2RY2UMPSP2RY6P2RY4SLC28A1 | |
| SCHEMBL17363860 | 0.83 | P2RY2 (0.58) | P2RY2UMPSP2RY6P2RY4P2RY14 | |
| SCHEMBL17363861 | 0.82 | P2RY2 (0.63) | P2RY2UMPSP2RY6P2RY4P2RY14 | |
| SCHEMBL1363428 | 0.82 | P2RY2 (0.63) | P2RY2UMPSP2RY6P2RY4P2RY14 | |
| SCHEMBL15196242 | 0.82 | P2RY2 (0.63) | P2RY2UMPSP2RY6P2RY4P2RY14 | |
| SCHEMBL15522444 | 0.82 | P2RY2 (0.63) | P2RY2UMPSP2RY6P2RY4P2RY14 | |
| SCHEMBL12143118 | 0.82 | P2RY2 (0.63) | P2RY2UMPSP2RY6P2RY4P2RY14 | |
| SCHEMBL15196259 | 0.82 | P2RY2 (0.63) | P2RY2UMPSP2RY6P2RY4P2RY14 | |
| SCHEMBL12143540 | 0.82 | P2RY2 (0.63) | P2RY2UMPSP2RY6P2RY4P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030166896-A1 | Base-modified enzymatic nucleic acid | RIBOZYME PHARMACEUTICALS, INC. | 2003-09-04 | — | — | US | disclosed |
| US-6528639-B2 | Active ribozyme | RIBOZYME PHARMACEUTICALS, INC. | 2003-03-04 | — | — | US | disclosed |
| US-20010006801-A1 | BASE-MODIFIED ENZYMATIC NUCLEIC ACID | USMAN NASSIM (US) | 2001-07-05 | — | — | US | disclosed |
| US-5891684-A | RIBOZYMES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-04-06 | — | — | US | disclosed |
| US-5879938-A | RIBOZYME WITH INCREASED ACTIVITY BY SUBSTITUTION OF MODIFIED NUCLEOTIDE INTO SUBSTRATE BINDING ARM OR CATALYTIC CORE | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-03-09 | — | — | US | disclosed |
| US-5767263-A | Base-modified enzymatic nucleic acid | RIBOZYME PHARMACEUTICALS, INC. (US) | 1998-06-16 | — | — | US | disclosed |
| EP-0799313-A2 | METHOD AND REAGENT FOR TREATMENT OF ARTHRITIC CONDITIONS, INDUCTION OF GRAFT TOLERANCE AND REVERSAL OF IMMUNE RESPONSES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1997-10-08 | — | — | EP | disclosed |
| US-5672511-A | Base-modified enzymatic nucleic acid | RIBOZYME PHARMACEUTICALS, INC. (US) | 1997-09-30 | — | — | US | disclosed |
| US-5672501-A | Base-modified enzymatic nucleic acid | RIBOZYME PHARMACEUTICALS, INC. (US) | 1997-09-30 | — | — | US | disclosed |
| WO-1996018736-A2 | METHOD AND REAGENT FOR TREATMENT OF ARTHRITIC CONDITIONS, INDUCTION OF GRAFT TOLERANCE AND REVERSAL OF IMMUNE RESPONSES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1996-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166896-A1 | Base-modified enzymatic nucleic acid | RNASE1, RNGTT, RNASEL | P2RY2 4422/4885UMPS 115/4885P2RY6 3658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.